Table 4. Univariate and multivariate analysis for OS ¶ and PFS ¶ .
| OS | PFS | |||||||
|---|---|---|---|---|---|---|---|---|
| UNIVARIATE | MULTIVARIATE | UNIVARIATE | MULTIVARIATE | |||||
| Variable | Hazard ratio (95% CI) | P-value | Hazard ratio (95% CI) | P-value | Hazard ratio (95% CI) | P-value | Hazard ratio (95% CI) | P-value |
| mResponse Class I (vs II,III,IV) | 0.58 (0.36 to 0.92) | 0.02 | 0.56 (0.35 to 0.89) | 0.01 | 0.34 (0.21 to 0.56) | <0.001 | 0.29 (0.17 to 0.49) | <0.001 |
| ECOG PS 1 (vs 0) | 1.18 (0.74 to 1.88) | 0.49 | 1.21 (0.77 to 1.92) | 0.41 | ||||
| Number of previous chemotherapy lines (1 to 6) | 0.89 (0.73 to 1.10) | 0.28 | 0.88 (0.69 to 1.11) | 0.27 | ||||
| Previous treatment with bevacizumab (vs no) | 1.69 (1.05 to 2.72) | 0.03 | 1.80 (1.10 to 2.92) | 0.02 | 1.86 (1.16 to 2.98) | 0.01 | 1.80 (1.12 to 2.91) | 0.02 |
| KRAS mutation (vs WT) | 0.72 (0.45 to 1.13) | 0.16 | 1.01 (0.65 to 1.58) | 0.95 | ||||
| BMI ≥25 (vs <25) | 0.55 (0.34 to 0.87) | 0.01 | 0.50 (0.31 to 0.81) | 0.004 | 0.72 (0.46 to 1.14) | 0.16 | ||
| Age | 0.98 (0.96 to 1.01) | 0.15 | 0.98 (0.96 to 1.01) | 0.15 | ||||
| Male (vs female) | 0.68 (0.43 to 1.07) | 0.09 | 0.62 (0.39 to 0.98) | 0.04 | 0.53 (0.33 to 0.87) | 0.01 | ||
| Occurrence HFSR before 2 nd FDG PET-CT(vs no) | 0.54 (0.33to 0.89) | 0.02 | 0.49 (0.30 to 0.81) | 0.005 | 0.87 (0.55 to 1.38) | 0.54 | ||
| Occurrence HSFR * (vs no) | 0.59 (0.37 to 0.95) | 0.03 | 0.81 (0.51 to 1.27) | 0.35 | ||||
* Time dependent variable;
¶ from date second FDG PET-CT